Intervacc

I början av december 2011 påbörjade vi ytterligare en durationsstudie på AHT, där vaccinskyddet undersöks sex månader efter avslutade grundvaccinationer. Resultaten från denna förmodade finala studie kommer att rapporteras tidigast i november 2012.
Read more...

The results are very encouraging in that it was found that a very low dose of antigen led to the same level of protection as using ten times higher.
Read more...

Intervacc AB held its Annual General Meeting June 9 in Hägersten. At the meeting the Company’s earnings and balance sheet for the fiscal year 2010 were approved. The Board of Directors and CEO were discharged from liability for the fiscal year 2010.
Read more...

Swedish Television about the new vaccine that gives hope >>